CAR-CIK细胞选择性归巢至骨髓微环境增强对急性髓系白血病负荷的控制
研究在CD33.CAR-CIK细胞中过表达野生型CXCR4和变异型CXCR4R334X,体外趋化性显著改善且细胞毒性未受损,体内骨髓归巢增强;但仅共表达野生型CXCR4的CAR-CIK细胞表现出更持久的体内抗白血病活性和延长动物生存,提示CXCR4可能以非经典方式调节CAR-CIK功能。
要点
- 过表达CXCR4wt和CXCR4mut均显著改善CD33.CAR-CIK对重组CXCL12或骨髓基质细胞条件培养基的趋化性,体外细胞毒性未受损。
- CXCR4过表达的CD33.CAR-CIK体内骨髓归巢增强,CXCR4R334X变异型滞留时间延长。
- 仅共表达CXCR4wt而非CXCR4mut的CD33.CAR-CIK表现出更持久的体内抗白血病活性并延长动物生存。
核心结论
- 数据提示,为CAR-CIK细胞装备CXCR4可能是提高其治疗急性髓系白血病潜力的有前景策略。
- 仅共表达CXCR4wt而非CXCR4mut的CD33.CAR-CIK表现出更持久的体内抗白血病活性并延长动物生存,提示CXCR4在调节CAR-CIK功能中具有不依赖骨髓归巢的非经典作用。
研究设计与样本
- 研究将传统CD33.CAR-细胞因子诱导的杀伤细胞(CIK)改造为过表达野生型CXCR4和变异型CXCR4R334X。
- CXCR4R334X变异型与疣、低丙种球蛋白血症、免疫缺陷和骨髓滞留综合征患者白细胞滞留于骨髓有关。
主要发现
- 过表达CXCR4wt和CXCR4mut的CD33.CAR-CIK对重组CXCL12或骨髓基质细胞条件培养基的趋化性显著改善,体外细胞毒性潜力未见受损。
- CXCR4过表达的CD33.CAR-CIK体内骨髓归巢增强,CXCR4R334X变异型滞留时间延长。
- 仅共表达CXCR4wt而非CXCR4mut的CD33.CAR-CIK表现出更持久的体内抗白血病活性并延长动物生存。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute myeloid leukemia (AML) is a hematological malignancy derived from neoplastic myeloid progenitor cells characterized by abnormal clonal proliferation and differentiation. Although novel therapeutic strategies have recently been introduced, the prognosis of AML is still unsatisfactory. So far, the efficacy of chimeric antigen receptor (CAR)-T-cell therapy in AML has been hampered by several factors, including the poor accumulation of the blood-injected cells in the leukemia bone marrow (BM) niche in which chemotherapy-resistant leukemic stem cells reside. Thus, we hypothesized that overexpression of CXCR4, whose ligand CXCL12 is highly expressed by BM stromal cells within this niche, could improve T-cell homing to the BM and consequently enhance their intimate contact with BM-resident AML cells, facilitating disease eradication. Specifically, we engineered conventional CD33.CAR-cytokine-induced killer cells (CIKs) with the wild-type (wt) CXCR4 and the variant CXCR4R334X, responsible for leukocyte sequestration in the BM of patients with warts, hypogammaglobulinemia, immunodeficiency, and myelokathexis syndrome. Overexpression of both CXCR4wt and CXCR4mut in CD33.CAR-CIKs resulted in significant improvement of chemotaxis toward recombinant CXCL12 or BM stromal cell-conditioned medium, with no observed impairment of cytotoxic potential in vitro. Moreover, CXCR4-overexpressing CD33.CAR-CIKs showed enhanced in vivo BM homing, associated with a prolonged retention for the CXCR4R334X variant. However, only CD33.CAR-CIKs coexpressing CXCR4wt but not CXCR4mut exerted a more sustained in vivo antileukemic activity and extended animal survival, suggesting a noncanonical role for CXCR4 in modulating CAR-CIK functions independent of BM homing. Taken together, these data suggest that arming CAR-CIKs with CXCR4 may represent a promising strategy for increasing their therapeutic potential for AML.
引用
- Biondi M, Tettamanti S, Galimberti S, et al. Selective homing of CAR-CIK cells to the bone marrow niche enhances control of the acute myeloid leukemia burden. Blood. 2023. PMID: 36787509. doi:10.1182/blood.2022018330
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。